Molecular Partners Reports H1 2023 Corporate Highlights and Financials
The first clinical trial of a new type of T cell engager candidate has been announced at the Advertising and Clinical Advisory Council (asco), according to latest data released by the company's chief medical officer, Colin Powell.
Source: streetinsider.comPublished on 2023-08-24
Related news
- Teck Resource coal spinoff shows power of sustainable finance movement : experts
- COSO guidance helps accountants deal with ESG and internal controls
- BrightView Holdings , Inc . ( NYSE : BV ) Q1 2023 Earnings Call Transcript
- Activist Greenwashing Case In D . C . Runs Aground - Consumer Law
- ESG Litigation and Regulatory Enforcement Actions : Positioning Your Company to Avoid What Coming | Orrick , Herrington & Sutcliffe LLP
- Streaming platforms vs . Media sovereignty : Netflix and others challenge national broadcasters
- Carney , Kyte oversee carbon offset rules to address greenwashing concerns
- Chord Energy Corporation Reports Financial and Operating Results for First Quarter 2023 , Declares Base and Variable Dividends and Issues Second Quarter Outlook
- Investegate |Tintra PLC Announcements | Tintra PLC : Repayment Under Placement Facility
- Triple Flag Announces Record Q2 2023 Results and Dividend Increase
- Athletes are speaking up against fossil fuel sponsorship . Why now ?
- Greta Thunberg calls COP26 a failure and a PR event , as Glasgow sees thousands attending climate marches
- Infosys Recognized as Global Top Employer for the Second Consecutive Year ; Ranked # 1 in India Again
- Sustainable economy : Parliament adopts new reporting rules for multinationals
- SEC Climate Disclosure Plan Could Be In Trouble After A Re ...